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Abstract
In order to understand how West Nile virus (WNV) has evolved since its introduction into North America, we have studied the genetic
and phenotypic variation among WNV isolates collected in various areas during consecutive transmission seasons. The present report
describes for the first time phenotypic changes occurring in the North American WNV population. Several isolates collected in Texas during
2003 display a small plaque (sp) and temperature sensitive (ts) phenotype, as well as reduced replication in cell culture, in comparison to
isolates collected in 2002 and New York in 1999. Studies of mouse neuroinvasiveness/neurovirulence also indicate that several of these
isolates were attenuated in neuroinvasiveness, but not for neurovirulence. The complete genome and deduced amino acid sequences of
several of these isolates have been determined in order to map the mutations responsible for this phenotypic variation. These data indicate
microevolution of WNV and the emergence of isolates exhibiting phenotypic variation.
D 2004 Elsevier Inc. All rights reserved.
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West Nile virus (WNV) is a single stranded, positive-
sense RNA virus belonging to the genus Flavivirus (family
Flaviviridae). Historically, human infections with WNV, a
member of the Japanese encephalitis serocomplex, usually
were associated with a mild undifferentiated fever (Monath
and Heinz, 1996). However, recent outbreaks in Europe,
Israel, and North America involving humans, equines, and
birds have been associated with significant rates of neuro-
logical disease (Lanciotti et al., 1999; Solomon and Vaughn,
2002). Until 1999, the geographical distribution of the virus
was limited to Africa, the Middle East, India, and western0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: abarrett@utmb.edu (A.D.T. Barrett).and central Asia with occasional epizootics and epidemics
in Europe (Murgue et al., 2002). But since the summer of
1999, the distribution of WNV has expanded to include 46
states of the continental US and seven Canadian provinces,
as well as Mexico, and most likely a number of Caribbean
Islands (Blitvich et al., 2003; Dupuis et al., 2003; Estrada-
Franco et al., 2003; Komar et al., 2003b; Quirin et al.,
2004). As WNV has spread across North America, the
number of human and veterinary cases and deaths has
continued to rise, resulting in the largest recorded epidemic
of arboviral encephalitis in the western hemisphere during
2002 (CDC, 2002). Because of its relatively recent
introduction, studies concerning the evolution of WNV are
important to understand the extent to which the virus has
mutated, as its temporal and geographic distribution have
expanded. Nucleic acid sequencing studies of WNV isolates
collected across the US since 1999 have identified
mutations to the genome when compared to the prototype
New York strain, WN-NY99 (GenBank accession no.04) 342–350
Fig. 1. Plaque morphology of WNV isolates. Vero cells in 6-well plates
were infected with WN-NY99, WNV 2002, WNV 2003 sp. Plaques were
visualized 3 days postinoculation by staining with crystal violet. Images
from pictures copied to Microsoft Photoshop and measured for plaque
diameter. Small plaque morphology measured as b1 mm. Large plaque
morphology measured as N1.5 mm. (A) WN-NY99, strain 382–99. (B)
WNV 2002. (C) Bird 1153 (2003). (D) Bird 1171 (2003).
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variants that group in a temporally and geographically
dependent manner (Beasley et al., 2003; Davis et al., 2003).
Following the introduction of WNV into Texas during
2002, studies were initiated to determine if phenotypic
changes also occurred among the genetic variants. Although
genetically distinct on a microevolutionary scale, previous
studies indicated that the phenotypic characteristics (i.e.,
plaque morphology, in vitro growth kinetics, neuroinvasive-
ness, and neurovirulence in a mouse model) of WNV
isolates collected in 2002 were not significantly different
from isolates collected in 1999 (Beasley et al., 2003).
During the 2003 transmission season, however, isolates of
WNV from both birds and mosquitoes collected in Texas
were recovered that produced small plaque (sp) morphology
and reduced virus yield at 72 h following infection in Vero
cells in comparison to isolates of WNV from previous
transmission seasons. Our results also indicated that several
of these isolates displayed a temperature-sensitive (ts)
phenotype and were attenuated for neuroinvasiveness in a
mouse model in comparison to the prototype WN-NY99
strain. Complete genome sequencing of several phenotypi-
cally distinct isolates was undertaken to identify potential
mutations in the WNV genome conferring these changes.
This is the first description of phenotypic variation among
WNV isolates in North America.Results
Identification of small plaque and temperature sensitive
isolates
Six of 29 isolates made during the 2003 transmission
season were identified with a sp phenotype (Fig. 1). All sp
isolates were collected in Harris Co. or Montgomery Co.,
TX and were made over a four-month period (May 09–
September 8, 2003). Each isolate was given a single
passage in Vero cells following initial isolation. Previous
studies with other related flaviviruses (yellow fever,
dengue, tick-borne encephalitis, St. Louis encephalitis,
and Japanese encephalitis viruses) have shown that some
viruses with sp phenotypes are also temperature-sensitive
(ts) when grown in cell culture at temperatures higher than
their permissive temperature (37.0 8C for WNV) (Blaney
et al., 2003; Eastman and Blair, 1985; Hollingshead et al.,
1983; Ledger et al., 1992; Wallner et al., 1996). Thus,
experiments were conducted to determine if sp and non-sp
producing isolates of WNV collected in 1999, 2002, and
2003 displayed a ts phenotype (Table 1). Three isolates
exhibiting a sp phenotype were identified as also having a
ts phenotype, while other sp and non-sp WNV isolates
collected during 1999, 2002, and 2003 did not. Following
the identification of isolates with sp and/or ts phenotypes,
in vitro multiplication studies were done comparing these
isolates to WN-NY99 (strain 382–99) and a 2002 largeplaque (lp), non-ts Texas WNV isolate (Bird 113). Results
from this analysis suggested that viral isolates with sp and/
or ts phenotypes have reduced levels of replication in Vero
cells at early time points in comparison to WN-NY99 and
isolates from 2002 with lp phenotypes (Fig. 2). These
isolates also exhibited a 1–2 log10 decrease in viral titer at
each time point during the course of infection and did not
reach the peak viral titers observed for other WNV isolates
at 72 h postinfection.
Mouse attenuation phenotypes
The identification of viral isolates exhibiting sp and/or ts
phenotypes with reduced replication in cell culture led us to
investigate the virulence phenotypes of these isolates using
a mouse model. Small plaque and ts phenotypes have
previously been shown to be indicative of attenuation of
neuroinvasiveness and neurovirulence in mouse models for
many of the encephalitic flaviviruses (Blaney et al., 2003;
Hanley et al., 2002, 2003; Puri et al., 1997; Wallner et al.,
1996). Consequently, each of the 2003 WNV isolates that
were tested for sp and ts phenotypes were also tested for
attenuation of neuroinvasiveness and neurovirulence in
female 3- to 4-week-old Swiss Webster mice. Using this
model, it has been possible to determine both intraperitoneal
(i.e., neuroinvasiveness) and intracranial (i.e., neuroviru-
lence) virulence values of several U.S. WNV isolates
colected prior to 2003. Because the intraperitoneal (ip)
LD50 of US WNV isolates from 1999 and 2002 ranged from
0.4 to 4.2 pfu, WNV isolates collected in 2003 were
screened for attenuation of neuroinvasiveness by adminis-
Table 1
sp, ts, and mouse attenuation phenotypes of West Nile viruses isolated in Texas, 2003
Virus Source Small
plaque
Mean virus titer (log10 PFU/ml)
at indicated temperature (8C)
Mouse neuroinvasiveness and neurovirulence
Vero Intraperitoneal
inoculation
Intracranial inoculation
37 8C 39.5 8C D LD50 (pfu) AST F SD
(days)
LD50
(pfu)
AST F SD
(days)
WN-NY99
(382-99)
Flamingo brain – 8.1 7.6 0.5 0.8 8.0 F 1.2 0.1 6.4 F 0.9
WN-99
(385-99)
Owl brain – 7 7.3 0.3 0.4 7.2 F 0.6 0.4 6.0 F 0.2
TWN 93
(2002)
Bird 113 – 7.9 7.7 0.2 0.5 8.0 F 1.0 0.1 6.7 F 0.3
TWN 84
(2002)
Bird 114 – 4.2 7.5 F 1.2 n.d. n.d.
TWN 117
(2002)
Bird 476
(Bolivar)
– 1.8 8.6 F 0.7 n.d. n.d.
2003
WNV
Isolates
TWN 269 Bird 1171 sp 6 3.3 2.7 z1000 n/a n.d. n.d.
TWN 270 Bird 1175 sp 3.5 1 2.5 z1000 n/a n.d. n.d.
TWN 271 Bird 1240 – 3.5 3.4 0.1 V100 8.0 F 2.0 n.d. n.d.
TWN 274 Bird 1153 sp 7.7 5 2.7 z1000 n/a 0.3 6.2 F 0.4
TWN 300 Bird 1427 – 5.4 5.9 0.5 V100 7.0 F 1.0 n.d. n.d.
TWN 301 Bird 1461 – 7 6.7 0.3 V100 7.0 F 1.0 0.2 6.2 F 0.6
TWN 302 Bird 1479 sp 6.3 7 0.7 z100 n/a n.d. n.d.
TWN 303 Bird 1481 – 6 6.2 0.2 V100 7 n.d. n.d.
TWN 304 Bird 1496 – 6.2 6.7 0.5 V100 7.2 F 1.0 n.d. n.d.
TWN 305 Bird 1519 sp 6.3 6.6 0.3 z1000 n/a 0.1 6.9 F 0.2
TWN 358 Mosq. v2769 – 6.1 6.3 0.2 V100 7.5 F 3.0 n.d. n.d.
TWN 359 Mosq. v3437 – 6.2 6.6 0.4 V100 7.0 F 1.0 n.d. n.d.
TWN 360 Mosq. v3567 – 7.1 6.7 0.4 V100 8.6 F 2.0 n.d. n.d.
TWN 361 Mosq. v3693 – 7.2 7.2 0 V100 8.4 F 1.0 n.d. n.d.
TWN 362 Mosq. v3941 – 7.2 7 0.2 V100 7.3 F 1.0 n.d. n.d.
TWN 363 Mosq. v3942 – 7.2 7.3 0.1 V100 8.2 F 1.0 n.d. n.d.
TWN 364 Mosq. v4007 – 8 8 0 V100 8.0 F 2.0 n.d. n.d.
TWN 365 Mosq. v4095 – 7.5 7.7 0.2 V100 8.4 F 1.5 n.d. n.d.
TWN 366 Mosq. v4181 – 7.9 8 0.1 V100 11 F 3.7 n.d. n.d.
TWN 367 Mosq. v4195 – 7.7 7.9 0.2 V100 7.2 F 1.3 n.d. n.d.
TWN 378 Bird 2071 – 8 7.9 0.1 V100 8.4 F 1.2 n.d. n.d.
TWN 379 Bird 2073 – 7.4 7.6 0.2 V100 8.1 F 2.0 n.d. n.d.
TWN 382 Mosq. v4369 sp 7.1 5.3 1.8 z1000 n/a 0.1 5.8 F 0.4
TWN 383 Mosq. v4380 mixed 6.6 6.3 0.3 z100 n/a n.d. n.d.
TWN 399 Bird 2066 – 7.8 7.7 0.1 V100 7.2 F 0.6 n.d. n.d.
TWN 400 Bird 2067 – 7.5 7.1 0.4 V100 7.1 F 0.2 n.d. n.d.
TWN 401 Bird 2075 – 7.9 7.7 0.2 V100 7.0 F 1.3 n.d. n.d.
TWN 402 Bird 1556 – 7.5 7.3 0.2 V100 7.8 F 2.0 n.d. n.d.
TWN 404 Bird 1881 mixed 6.4 7 0.3 z1000 n/a n.d. n.d.
sp = small plaque size at 37 8C; small plaques have a diameter of b1.0 mm compared to plaque diameter of 1.5–2.0 mm in Vero cells.
mixed = both small and large plaques measured.
D = Change in titer (log10 pfu/ml) at 39.5 8C compared to titer at permissive temperature (37.0 8C).
Underline indicates N2.5 log10 pfu/ml reduction in titer in Vero cells at 39.5 8C when compared to permissive temperature.
For a dose of 103 pfu of virus; only strains causing mortality in at least four of five animals have average survival time (AST).
z1000 indicates attenuated phenotype.
z100 = LD50 N100 pfu but b1000 pfu.
Note. n.d., not determined.
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isolate (Beasley et al., 2003; Table 1). After identification of
six isolates that were attenuated for neuroinvasiveness (ip
LD50 z 1000 pfu), the degree of attenuation of neuro-
virulence was examined for three of the attenuated isolates
(Bird 1153, Bird 1519, Mosquito V4369) by intracranial (ic)
inoculation. The results of these studies revealed thatisolates attenuated for neuroinvasiveness were not attenu-
ated for neurovirulence (Table 1).
Attenuation of mouse neuroinvasiveness
In order to establish the degree of attenuation of
neuroinvasiveness in a Swiss Webster mouse model, precise
Fig. 2. Viral growth curve of 2003 sp WNV isolates in comparison to
isolates from 1999 to 2002. Vero cells infected with WNV isolates at an
MOI of 0.1 pfu/cell in triplicate in 12-well plates. Virus titers were then
determined at indicated time points by plaque assay in Vero cells.
C.T. Davis et al. / Virology 330 (2004) 342–350 345neuroinvasiveness for sp and/or ts isolates that exhibited a
z1000 pfu LD50 was determined. The extent of attenuation
of neuroinvasiveness ranged from an ip LD50 of 2000 pfu
(Bird 1171) to 645,000 pfu (Mosq.v4369) representing up to
100,000-fold attenuation when compared to the prototypic
WNV isolate made in New York in 1999 (Table 2). Also, the
percent mortality following infection with each isolate was
greater at higher doses, suggesting the dose-dependent
manifestation of encephalitis in this mouse model (data
not shown). At 21 days post-inoculation (dpi), surviving
mice were challenged with 100 LD50 of WN-NY99 (strain
385–99) to measure the dose of each isolate required to
protect 50% of mice from death following challenge with a
highly neuroinvasive strain (PD50). These experiments
suggest that attenuated isolates administered at even very
low doses (101 to 100 pfu) are able to induce a protectiveTable 2
Mouse neuroinvasive/neurovirulence phenotypes
West Nile virus isolate ip LD50 (pfu) ic LD
WN-NY99 (382-99) 0.8 0.1
Texas 2002 (Bird 113) 0.5 0.1
Texas 2003 (Bird 1461) 0.6 0.2
Texas 2003 (Bird 1153) 23,000 0.3
Texas 2003 (Bird 1519) 51,000 0.1
Texas 2003 (Mosquito 4369) 645,000 0.1
Texas 2003 (Bird 1171) 2000 n.d.
Texas 2003 (Bird 1175) 10,000 n.d.
AST F SD (ip) = Average survival time.
ip PD50 = the number of pfu required to immunize mice by the ip route to prote
WN-NY99 (382–99).
P values determine by two-tailed Mann–Whitney test compared to WN-NY99. A
n.d. = not determined.immune response in the mouse. To test the mechanism by
which these isolates were attenuated, serum viremia curves
and brain infectivity levels were determined for a single sp,
ts, mouse attenuated WNV isolate (Bird 1153) and
compared to the levels of viremia in the mouse following
parallel infection with WN-NY99. Groups of mice were
infected ip with 103 pfu of either WN-NY99 (strains 382–
99) or isolate Bird 1153 and three mice from each group
were sacrificed daily for 8 days for collection of serum and
whole brain preparations. As expected, WN-NY99 followed
the typical course of infection of a highly neuroinvasive
WNV, whereby serum viremia increased daily following
inoculation, peaked at day 3, and was followed by the
detection of virus in the brain as early as day 4 and
continued until death at days 7–8 (Table 3). Isolate Bird
1153, however, did not produce increased levels of serum
viremia following infection. Viral titers remained at levels
comparable to the titer of the inoculum for at least 24 h post-
inoculation, but decreased by 48 or 72 h and became
undetectable in the serum by day 4. At an ip dose of 103 pfu,
no virus was detectable in the brains of these mice at any
time post inoculation. These results suggest that attenuation
of at least one of the non-neuroinvasive 2003 WNV isolates
is due to the inability of the virus to replicate to high levels
in the blood sufficient for the invasion of the central nervous
system of the mouse.
Nucleotide and deduced amino acid sequence comparisons
In order to determine those mutations to the WNV
genome responsible for the above phenotypic changes, the
complete viral genome of 2003 WNV isolate Bird 1153 was
sequenced (GenBank accession no. AY712945). Phyloge-
netic comparison of this sequence to all of the other
complete genomes of WNV available from GenBank
revealed that this isolate is a member of the North American
clade of WNV isolates (data not shown). While there were a
total of 36 nucleotide mutations in the genome of this virus
relative to the prototype WN-NY99 strain, these mutations
resulted in only 4 amino acid substitutions in the WNV50 (pfu) AST F SD ( P) ip PD50 (pfu)
7.5 F 0.6 1.3
8.0 F 1.0 (0.2)* 1.5
7.0 F 1.0 (0.7)* 1.2
9.5 F 1.0 (0.12)* 0.8
9.0 F 4.0 (0.15)* 0.4
8.3 F 3.0 (0.4)* 0.1
9.7 F 3.3 (0.1)* 1.0
9.3 F 6.0 (0.13)* 0.2
ct against challenge with 100 LD50.
sterisks indicate no significance.
Table 3
Serum and brain viremia in mice following ip inoculation of 103 pfu of
WN-NY99 (neuroinvasive) vs. Bird 1153 (non-neuroinvasive)
Days post
inoculation
Animal WN-NY99 (382-99) Bird 1153
Serum
titer
(pfu/ml)
Brain
titer
(pfu/brain)
Serum
titer
(pfu/ml)
Brain titer
(pfu/brain)
1 1 2000 – 3000 –
2 4000 – 1500 –
3 1400 – 4000 –
2 1 4000 – 1650 –
2 11,500 – 250 –
3 1650 – 750 –
3 1 17,000 – 100 –
2 15,000 – 100 –
3 6000 – 250 –
4 1 – 2000 – –
2 – 500 – –
3 – 4000 – –
5 1 – 3000 – –
2 – 1000 – –
3 – 750 – –
6 1 – 135,000 – –
2 – 300,000 – –
3 – 750,000 – –
7 1 – 1,150,000 n.d. n.d.
8 1 – 1,350,000 n.d. n.d.
– Indicates no virus detected.
C.T. Davis et al. / Virology 330 (2004) 342–350346polyprotein (prM-156, E-159, NS4B-249 and NS5-804) and
4 nucleotide substitutions in the 3VUTR (Table 4). In order
to identify nucleotide/amino acid substitutions shared by sp,
ts, and/or attenuated isolates, each of the genes/regions of
isolate Bird 1153 containing amino acid substitutions or
nucleotide mutations in the case of the 3VUTR was
sequenced in other isolates with a sp, ts, and/or attenuated
phenotype. Table 4 shows the distribution of mutations
among WNV isolates from 2002 and 2003 in comparison to
WN-NY99 in those genes/regions where mutations were
identified in the completely sequenced isolate. While several
conserved mutations were identified among isolates from
both 2002 and 2003, a single amino acid substitution
(NS4B-E249G) was found to be conserved in three isolates
with a sp, ts, and mouse-attenuated phenotype (Bird 1153,
Bird 1171, Bird 1175). Although this mutation was not
identified in all attenuated 2003 isolates, it is possible that
the substitution in NS4B was responsible for the altered
phenotype(s) of these three isolates. Comparisons of this
particular amino acid substitution between other North
American WNV isolates revealed that no other isolates
described to date contained this mutation. It is interesting to
note that several Old World WNV isolates (i.e., Volgograd,
Romania, Italy) contain different amino acid substitutions
other than EYG at residue 249 of NS4B (Lanciotti et al.,
2002). Because the complete genome sequence of Bird 1153
did not reveal a single nucleotide/amino acid substitution
shared only by sp and/or attenuated isolates, it seemed
evident that multiple mutations were likely to be responsible
for the range of phenotypes identified. Therefore, thecomplete genomes of three other 2003 WNV isolates (Bird
1461, GenBank accession no. AY712947; Bird 1171,
GenBank accession no. AY712946; and Mosquito V4369,
GenBank accession no. AY712948) were sequenced and
compared to WN-NY99 (382–99) to identify additional
mutations which were likely to be responsible for the
phenotypes (Table 4). With the exception of E-V159A,
nucleotide mutations in the genome of Bird 1461 (large
plaque, non-ts, non-attenuated) encoded four unique amino
acid substitutions compared with sp, ts, and/or attenuated
isolates (NS3-E180D; NS3-E327K; NS4A-V134M; NS5-
A618S). The genome sequence of Bird 1171 (sp, ts, and
attenuated) was nearly homologous to that of Bird 1153
with two additional amino acid substitutions (NS5-R199L;
NS5-A687D) and one additional substitution in the 3VUTR
(GYU at residue 11000). Mosquito V4369 (sp, non-ts,
attenuated) also shared the E-V159A amino acid substitu-
tion and the 3VUTR nucleotide change at residue 10851, but
this isolate revealed three additional amino acid substitu-
tions (prM-N4D; NS4B-T240A; NS5-H295Y) and an addi-
tional nucleotide change in the 3VUTR (AYU at residue
10984). The prM-N4D substitution found in Mosquito
V4369 was shared by another sp, non-ts, attenuated isolate,
Bird 1519, suggesting its possible role in the altered
phenotype(s) of these two isolates.Discussion
Our studies provide the first evidence of phenotypic
variation in the North American WNV population by the
characterization of isolates exhibiting small plaque morphol-
ogy, temperature-sensitivity, and attenuation in a mouse
model. Previous mouse virulence studies have shown that
both lineage 1 and 2 WNV isolates made from nature (i.e.,
mosquito pools, birds, horses, humans) differ in their ability
to replicate in peripheral tissues, induce viremia, and invade
the CNS (neuroinvasiveness), but that all strains are able to
initiate a cytopathic infection in the CNS and cause
encephalitis (neurovirulence) if virus is delivered directly
to the brain via intracranial inoculation (Beasley et al., 2002).
The present studies have shown similar findings in that
naturally acquired isolates, which were attenuated for
neuroinvasiveness, were not attenuated for neurovirulence.
Additionally, the manifestation of encephalitic disease in our
mouse model following infection with the 2003 attenuated
isolates appeared to be dose-dependent, suggesting that
invasion of the CNS is determined by the amount of virus
(level of viremia) circulating in the mouse. While this
observation may be relevant for our mouse model, other
species, such as birds and hamsters, are able to support
higher viremias, yet remain asymptomatic, while humans
and horses may develop encephalitis with a relatively low
transient viremia (Bunning et al., 2002; Komar et al., 2003a;
Xiao et al., 2001). Thus, it is likely that there are different
virulence determinants in different species, which may
Table 4
Nucleotide changes and deduced amino acid substitutions of 2002–2003 Texas WNV isolates compared to WN-NY99 (AF196835)
WNV isolate Mutations in UTR or in coding regions that result in an amino acid substitution
Nucleotide position Gene/region Nucleotide change Amino acid change
Harris Co., TX 2002, lp, non-ts,
non-attenuated
1442 E U to C V159A
7699 NS5 A to C T6P
10408 3V UTR C to U n/a
10851 3V UTR A to G n/a
Bolivar P., TX 2002*, lp, non-ts,
non-attenuated, D AY289214
1192 E A to G T76A
2749 NS1 A to G E94G
3937 NS2A G to A V138I
7432 NS4B G to A V173I
9256 NS5 C to U T526I
10494 3V UTR U to C n/a
10768 3V UTR U to A n/a
10851 3V UTR A to G n/a
Bird 1461*, lp, non-ts,
non-attenuated, D AY712947
1442 E U to C V159A
5151 NS3 A to U E180D
5593 NS3 G to A E327K
6871 NS4A G to A V134M
9535 NS5 G to U A618S
10408 3V UTR C to T n/a
10851 3V UTR A to G n/a
Bird 1153*, sp, ts, att, D AY712945 931 prM G to A V156I
1442 E U to C V159A
7661 NS4B A to G E249G
10091 NS5 C to U A804V
10596 3V UTR A to G n/a
10774 3V UTR C to U n/a
10799 3V UTR A to G n/a
10851 3V UTR A to G n/a
Bird 1171*, sp, ts, att, D AY712946 931 prM G to A V156I
1442 E U to C V159A
7661 NS4B A to G E249G
8279 NS5 G to U R199L
9743 NS5 C to A A687D
10091 NS5 C to U A804V
10596 3V UTR A to G n/a
10774 3V UTR C to U n/a
10799 3V UTR A to G n/a
10851 3V UTR A to G n/a
11000 3V UTR G to U n/a
Bird 1175, sp, ts, att 1442 E U to C V159A
7661 NS4B A to G E249G
10408 3V UTR C to U n/a
10851 3V UTR A to G n/a
Bird 1519, sp, att 478 prM A to G N4D
1442 E U to C V159A
10851 3V UTR A to G n/a
Mosq. V4369*, sp, att, D AY712948 478 prM A to G N4D
1442 E U to C V159A
7636 NS4B A to G T240A
8566 NS5 C to U H295Y
10851 3V UTR A to G n/a
10984 3V UTR A to U n/a
D = GenBank Accession No.
* Complete genome sequenced; others represent genes/regions of interest.
C.T. Davis et al. / Virology 330 (2004) 342–350 347influence the attenuation phenotypes of these isolates in
other animal models.
Although these experiments suggest that attenuation of
these isolates is related to their inability to replicate to titers
sufficient for the invasion of the CNS, the underlying
mechanism of attenuation remains unclear. Isolates from2003 had a range of phenotypic properties (Table 1) and
sequencing data suggested that these were not all attributable
to a single widespread mutation. Therefore, analysis of
multiple variants is likely to identify multiple mutations that
affect a range of phenotypic properties, including mouse
virulence phenotypes. For those isolates that exhibited a ts
C.T. Davis et al. / Virology 330 (2004) 342–350348phenotype, it is possible that the mechanism of attenuation
was the result of viral replication being sensitive to the
temperature of the mouse following infection and induction
of fever. Although ts variants of WNVand other flaviviruses
have been produced in vitro by either cell culture passage or
chemical mutagenesis (Blaney et al., 2003; Dunster et al.,
1990; Hanley et al., 2002), to our knowledge, the natural
occurrence of WNV isolates exhibiting temperature sensi-
tivity has not been previously reported. The higher body
temperatures of avian species may be a selective factor in the
emergence of ts variants. Additional in vivo bird experiments
will be necessary to address this question. It has been
hypothesized that mutations to viral genes that encode
proteins with enzymatic functions may result in generation
of virus variants with a temperature-sensitive phenotype.
This is because every enzyme has an optimal temperature for
activity, leading to a decline in its functional role in viral
replication at suboptimal temperatures. Similarly, mutations
may destabilize the conformation of the enzyme by breaking
bonds between amino acids important in the active site and
protein stability. Conformational instability of the enzyme
may then result in suboptimal enzyme-substrate binding. In
support of this hypothesis, mutations to the non-structural
protein genes (i.e., NS1, NS3, NS5) of mosquito-borne
flaviviruses have been correlated with the generation of a
temperature-sensitive phenotype (Blaney et al., 2003;
Hanley et al., 2002; Muylaert et al., 1997). However, it is
possible that structural genes may also result in a temper-
ature-sensitive phenotype if the conformational stability of,
for example, the envelope protein is affected. Finally, it is
unknown whether or not the attenuated phenotype of these
isolates will be retained in other susceptible hosts, such as
birds, horses, or humans. However, it would be expected that
variants will arise that are attenuated for a variety of hosts,
including birds, equines, and/or humans. Further studies are
warranted to investigate if there is a selection for WNV
variants with modified phenotypes. Continued genetic and
phenotypic characterization of WNV isolates made in North
America will improve our understanding of the relationship
between viral evolution and phenotypic variation in an
emerging viral population and how these factors influence
the epidemiology of WNV in North America.Materials and methods
Collection of isolates
Dead birds and mosquitoes were collected by the Harris
County Mosquito Control Division from Harris and Mont-
gomery Co., TX during the summer of 2003. Virus isolations
were made by inoculation of bird brain or mosquito
homogenates on Vero cells as described elsewhere (Lilli-
bridge et al., 2004). Upon confirmation that isolates were
WNV positive by either hemagluttination inhibition assay or
RT-PCR, each isolate was passaged once in Vero cells toderive virus for use in these studies and was submitted to the
World Reference Center for Emerging Viruses and Arbovi-
ruses at the University of Texas Medical Branch.
Small plaque (sp) morphology and temperature-sensitivity
(ts) assays
In order to establish the plaque morphology and ts
phenotypes of isolates collected in 2003, plaque assays were
carried out by infecting monolayer cultures of Vero cells
(ATCC) in 6-well plates with serial dilutions of WNV
isolates. All plaque assays were run in parallel with WN-
NY99 (strain 382–99) as a control. Each isolate was grown
at both 37.0 and 39.5 8C for 72 h to measure temperature-
sensitivity, plaque morphology, and plaque titer. At 72 h
post-infection, wells were stained with crystal violet to
visualize plaques. The small plaque (sp) phenotype was
described as a b1.0 mm plaque diameter whereas large
plaque (lp) WNV was N1.5 mm in plaque diameter. The ts
phenotype was described as a z2.5 log10 reduction in
infectivity titer determined in Vero cell plaque assay at 39.5
8C when compared to permissive temperature 37.0 8C.
In vitro growth kinetics
Growth curves were performed in triplicate by infecting
Vero cells in 12-well plates with WNV isolates at an MOI of
0.1 pfu/cell. A low MOI was used in order to compare the
multiplication kinetics of the variant viruses as a contribu-
ting factor to their attenuated phenotype rather than to
compare their replication kinetics in a single step growth
curve. Supernatants were then harvested at 0, 12, 24, 48, 72,
and 96 h post-infection. Vero cell plaque assays were used
to determine mean virus titers at each time point.
Mouse attenuation studies
Screening WNV isolates for attenuation of neuroinva-
siveness was performed by intraperitoneal (ip) inoculation
of groups of five females, 3-to 4-week-old Swiss Webster
mice with 100 AL of 102 and 103 pfu of virus. WN-NY99
(isolate 385–99) was used as a positive control; mice
inoculated with saline served as negative controls. Mice
were evaluated daily for signs of illness (ruffled fur,
hunched posture, lethargy, ocular or nasal discharge,
hindlimb/forelimb paralysis) or death. All deaths occurred
between twice-daily observations. At 21 days post-inocu-
lation (dpi), surviving mice were challenged with 100 LD50
of WN-NY99 (385–99) to ensure that replication of virus
had occurred in each mouse inoculated, as indicated by
protection following challenge with a lethal dose. In order
to determine if isolates that were attenuated in neuro-
invasiveness were also attenuated for neurovirulence,
attenuated isolates (20 AL) were inoculated intracerebrally
into groups of five females 3- to 4-week-old Swiss
Webster mice at dosages of 103 to 101 pfu of virus.
C.T. Davis et al. / Virology 330 (2004) 342–350 349Severe illness and/or death were the end-points as before.
All procedures with animals were carried out according to
guidelines of the Committee on Care and Use of
Laboratory Animals under an animal care protocol
approved by the University of Texas Medical Branch.
All work with infected animals and virus was carried out
in Biosafety Level 3 facilities.
Determination of LD50
In order to establish the extent of attenuation of neuro-
invasiveness in a Swiss Webster mouse model, a precise
LD50 for WNV isolates that exhibited a z1000 pfu LD50
was determined. This was done by intraperitoneal (ip)
inoculation of groups of five females, 3- to 4-week-old
Swiss Webster mice with 100 AL of serial 10-fold dilutions
of virus from 106 to 101 pfu of virus. WN-NY99 (385–99)
was used as a positive control. Mice were evaluated for
signs of illness or death as before. At 21 days post-
inoculation (dpi), surviving mice were challenged with 100
LD50 of WN-NY99 (385–99) to ensure replication of virus
and to calculate the dose that protects 50% of mice from
death against a lethal challenge of WN-NY99 (PD50).
Viremia kinetics and brain infectivity levels of an attenuated
WNV isolate
The 3- to 4-week-old Swiss Webster mouse model was
used to compare the viremia and brain infectivity levels of
an attenuated WNV isolate to the highly neuroinvasive
WNV isolate, WN-NY99. Two groups of 24 mice were
infected ip with 100 AL of 103 pfu of either WN-NY99
(385–99) or an attenuated 2003 WNV isolate (Bird 1153)
and monitored daily for signs of illness. Following
infection, three mice from each of the two groups were
bled daily for 8 days and serum samples were titrated, using
standard Vero cell viral plaque assays in 6-well plates.
Briefly, animals were bled daily by cardiac puncture after
euthanasia in order to recover at least 2 ml of whole blood.
Blood was allowed to clot and then centrifuged; the serum
was extracted and diluted 101 to 106 for titration by
plaque assay. Virus titers in brain were measured daily by
removing the entire brain from each of three euthanized
mice, followed by homogenization in 2% MEM. Brain
homogenates were then diluted 101 to 106 for titration by
plaque assay. Virus titers in blood and brain at each time
interval were measured in three mice and the averages of
these were used to construct a viremia and brain infectivity
curve. These results were compared to a viremia curve and
brain infectivity curve for WN-NY99, which was performed
in parallel under the same experimental conditions. All
procedures were carried out according to guidelines of the
Committee on Care and Use of Laboratory Animals under
an animal care protocol approved by the University of Texas
Medical Branch. All work with infected animals and virus
was carried out in Biosafety Level 3 facilities.RNA extraction, reverse transcription (RT), and PCR for
genome sequencing
Viral RNA was extracted directly from 140 AL of
infected Vero or BHK cell culture supernatants using the
QiaAMP viral RNA extraction kit (Qiagen). RT was
performed in a 50 AL volume containing 5 AL of viral
RNA, 1 AL of random hexamer primer, 10 AL of 5 RT
buffer, 4 AL of 10 mM dNTPs, 0.4 AL of cloned RNAse
inhibitor, 0.5 AL of Moloney murine leukemia virus
(MMLV) reverse transcriptase, and 29.1 AL of HPLC water.
PCR was performed in a 25-AL volume containing 2.0 AL
cDNA template from RT, 1.0 AL forward primer, 1.0 AL
reverse primer, 2.5 AL 10X PCR buffer, 0.5 AL 10 mM
dNTPs, 0.5 AL of 1 U/AL Taq polymerase, and 17.5 AL of
HPLC water. For complete genome sequencing and
sequencing of genes/regions of interest, primer sets were
designed based on the genome of WN-NY99 (382–99).
PCR products were then gel purified using the QIAquick kit
(Qiagen) according to the manufacturer’s protocol, and the
resulting template was directly sequenced using the ampli-
fying primers. Sequencing reactions were performed in the
UTMB Biomolecular Resource Facility’s DNA sequencing
laboratory. Analysis and assembly of sequencing data was
performed using the Vector NTI Suite software package
(Informax). Nucleotide and deduced amino acid sequences
of the complete genome of each isolate were aligned using
the AlignX program in the Vector NTI Suite and then
compared to a previously published sequence of WN-NY99
(GenBank accession no. AF196835).Acknowledgments
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